Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Experimental justification of the use of bioingineering construction for occlusive vascular diseases treatment

Authors: Skhirtladze I.D., Muradyan M.V., Tkhagapsova M.M., Chigogidze N.A.

Company:
A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Russian Academy of Medical Sciences, Rublevskoe shosse, 135, Moscow, 121552, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2014; (): -

Quote as: Skhirtladze I.D., Muradyan M.V., Tkhagap- sova M.M., Chigogidze N.A. Experimental justifica- tion of the use of bioingineering construction for occlusive vascular diseases treatment. Klinicheskaya Fiziologiya Krovoobrashcheniya. 2014; 2: 48–53.

Full text:  

Abstract

Objective: development, production and experimental use of bioengineering construction for the treatment of occlusive vascular diseases. The developed bioengineering construction consists of a frame and fixed to it a live cell culture. This frame may be made either of metal or polymeric material. In a most preferred embodiment, the construction frame may be formed as stent in which the stiffening ribs are provided with fixed cell culture wells. The above-mentioned live cell culture preferably comprises autogenic or allogenic cells, which can be fibroblasts or multipotent mesenchymal stromal cells. A stent implantation in experimental animals (7 mongrel dogs) was performed under intravenous anesthesia. A selective angiography was performed in all experiments 70 days after operations to assess the patency of stents coated with cul- tured fibroblasts. It was a good positioning of the stent and there were no visible deformation of the arteries or distal throm- bosis. While, none of the dogs received disaggregative or other therapy. All experimental animals underwent angiography and were euthanized. The aortal parts with the renal arteries and kidneys were got after autopsy. The stented parts of renal arteries were endothelializied even layer. On a section, we could clearly see location of the stent cells relative to the vessel wall thickness.

References

1. Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирур- гия – 2008. М.: НЦССХ им. А.Н. Бакулева РАМН; 2009.
2. Бабунашвили А.М., Иванов В.А. Применение коронар- ного стентирования в зависимости от клинической кар- тины ИБС и типа атеросклеротического поражения ко- ронарного русла. М.; 2000.
3. Haundenschild C.C. Pathobiology of restenosis after angio- plasty. Am. J. Med. 1993; 94: 40–4.
4. Holmes D., Fitzgerald P., Goldberg S., La Blanche J., Lin- coff A.M., Savage M. et al. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a doublе- blind, placebo-controlled trial. Am. Heart J. 2000; 139: 23–31.
5. Mintz G.S., Popma J.J., Pichard A.D., Kent K.M., Sat- ler L.F., Wong C. et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996; 94: 35–43.
6. Бокерия Л.А., Алекян Б.Г. Руководство по рентгеноэндо- васкулярной хирургии сердца и сосудов. М.: НЦССХ им. А.Н. Бакулева РАМН; 2007.
7. Осиев А.Г. Факторы риска и предикторы успеха чрескож- ных коронарных вмешательств у больных с хронически- ми окклюзиями коронарных артерий. Патология кровооб- ращения и кардиохирургия. 2004; 4: 4–8.
8. Di Mario C., Werner G.S., Sianos G., Galassi A.R., Büttner J., Dudek D. et al. European perspective in recanalisation of chronic total occlusions (CTO): consensus document from the EuroCTO Club. Eurointerv. 2007; 3: 30–43.
9. Grantham J.A., Marso S.P., Spertus J., House J., Hol- mes D.R. Jr, Rutherford B.D. et al. Chronic total occlusion angioplasty in the United States. JACC Cardiovasc. Interv. 2009; 2 (6): 479–86.
10. Prasad A., Rihal C.S., Lennon R.J., Wiste H.J., Singh M., Holmes D.R. Jr et al. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: 25 years experience from the Mayo Clinic. J. Am. Coll. Cardiol. 2007; 49 (15): 1611–8.
11. Stone G.W., Kandzari D.E., Mehran R., Colombo A., Schwartz R.S., Bailey S. et al. Percutaneous recanalisation of chronically occluded coronary arteries: a consensus Do- cument: Part I. Circulation. 2005; 112: 2364–72.
12. Chevalier B., Serruys P.W., Silber S., Garcia E., Suryaprana- ta H., Hauptmann K. et al. Randomized controlled trial between biolimus-eluted Nobori and paclitaxel-eluted Taxus coronary stents. Eurointervention. 2007; 2: 426–34.
13. Waksman R. Biodegradable stents: they do their job and disap- pear. J. Invasive. Cardiol. 2006; 18 (2): 70–4.
14. Beatt K., Serruys P.W., Hugenholtz P.G. Restenosis after coro- nary angioplasty: New standarts of clinical studies. J. Am. Coll. Cardiol. 1990; 15(2): 491–8.
15. Virmani R., Farb A., Guagliumi G., Kolodgie F.D. Drug-elut- ing stents: Caution and concerns for long-term outcome. Coron. Artery Dis. 2004; 15: 313–8.

 If you found mistakes, select text and press Alt+A